COVID-CP Banking

Establishment of COVID-19 Convalescent Plasma Banking System in Japan - COVID-CP Banking

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1030200279

Enrollment

100

Registered

2020-12-25

Start date

2020-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronavirus disease 2019 COVID19 Plasma therapy Biobank Biobanking

Interventions

Plasma of a person who has recovered from infection and who is negative for the new coronavirus (SARS-CoV-2) and has a high neutralizing antibody titer should be collected using a component blood samp

C000705128

COVID-19, Convalescent Plasma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Blood type (ABO, Rh type) and irregular antibody are negative (Keio University Hospital) (2) The following infectious disease screening antigen antibody test is negative or within the blood donation standard range: syphilis serological test, hepatitis B virus test (HBs antigen, HBs antibody, HBc antibody), hepatitis C virus test (HCV antibody) ), HIV test (HIV-1, 2 antibody), HTLV-1 antibody test, human parvovirus test, nucleic acid amplification test (HBV, HCV, HIV) (when antibody test of each virus becomes positive) (consigned to Nisseki And carry out) (3) SARS-CoV-2 neutralizing antibody titer (conducted at National Institute of Infectious Diseases Toyama Government Building) is high titer positive (1: 160 or more is a guide). (4) SARS-CoV-2 blood PCR (conducted at the National Institute of Infectious Diseases Murayama Government Building) is negative.

Exclusion criteria

Exclusion criteria: 1) A clinically meaningful irregular antibody becomes positive, 2) The infectious disease screening is positive or out of the blood donation standard range. 3) SARS-CoV-2 neutralizing antibody titer was judged to be low (1:80 or less is a guideline. Since the criteria are not sufficiently standardized, it will be decided in consultation with the National Institute of Infectious Diseases) 4) SARS-CoV-2 PCR is positive 5) The person in charge of business determines that it is inappropriate

Design outcomes

Primary

Measure	Time frame
Safety of COVID-19 CP donor	—

Secondary

Measure	Time frame
Feasibility of COVID-19 CP Banking	—

Contacts

Public ContactRie Yamazaki

Keio University School of Medicine

r-yamazaki@keio.jp+81-3-5363-3715

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026